PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 491/22, A61K 31/435, 31/44 — A1

(11) International Publication Number: WO 99/03859

(43) International Publication Date: 28 January 1999 (28.01.99)

(21) International Application Number: PCT/SE98/01364

(22) International Filing Date: 10 July 1998 (10.07.98)

(30) Priority Data:

9702746-0	18 July 1997 (18.07.97)	SE
9800977-2	24 March 1998 (24.03.98)	SE

(71) Applicant *(for all designated States except US)*: ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: PHILLIPS, Eifion [GB/US]; Astra Arcus USA, Inc., P.O. Box 20890, Rochester, NY 14603 (US). MACK, Robert [US/US]; Astra Arcus USA, Inc., P.O. Box 20890, Rochester, NY 14603 (US). MACOR, John [US/US]; 250 Kuhl Road East, Flemington, NJ 08822 (US). SEMUS, Simon [US/US]; 1530 Neshaminy Valley Drive, Bensalem, PA 19020 (US).

(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: NOVEL SPIROAZABICYCLIC HETEROCYCLIC COMPOUNDS

(57) Abstract



(I)

A compound of formula (I) wherein n is 0 or 1; m is 0 or 1; p is 0 or 1; X is oxygen or sulfur; Y is CH, N or NO; W is oxygen, H_2 or F_2; A is N or $C(R^2)$; G is N or $C(R^3)$; D is N or $C(R^4)$; with the proviso that no more than one of A, G, and D is nitrogen, but at least one of Y, A, G, and D is nitrogen or NO; R^1 is hydrogen or C_1 to C_4 alkyl; R^2, R^3, and R^4 are independently hydrogen, halogen, C_1–C_4 alkyl, C_2–C_4 alkenyl, C_2–C_4 alkynyl, aryl, heteroaryl, OH, OC_1–C_4 alkyl, CO_2R^1, –CN, $–NO_2$, $–NR^5R^6$, $–CF_3$, $–OSO_2CF_3$ or R^2 and R^3, or R^3 and R^4, respectively, may together form another six membered aromatic or heteroaromatic ring sharing A and G, or G and D, respectively, containing between zero and two nitrogen atoms, and substituted with one to two of the following substituents: independently hydrogen, halogen, C_1–C_4 alkyl, C_2–C_4 alkenyl, C_2–C_4 alkynyl, aryl, heteroaryl, OH, OC_1–C_4 alkyl, CO_2R^1, –CN, $–NO_2$, $–NR^5R^6$, $–CF_3$, $–OSO_2CF_3$; R^5 and R^6 are independently hydrogen, C_1–C_4 alkyl, $C(O)R^7$, $C(O)NHR^8$, $C(O)OR^9$, SO_2R^{10} or may together be $(CH_2)_jQ(CH_2)_k$ where Q is O, S, NR^{11}, or a bond; j is 2 to 7, k is 0 to 2; R^7, R^8, R^9, R^{10}, and R^{11} are independently C_1–C_4 alkyl, aryl, or heteroaryl, or an enantiomer thereof, and the pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.